Alto Neuroscience Amends S-1, Nears Public Offering

Ticker: ANRO · Form: S-1/A · Filed: 2024-01-29T00:00:00.000Z

Sentiment: neutral

Topics: IPO, S-1/A, pharmaceuticals, public-offering

TL;DR

**Alto Neuroscience is prepping for its IPO, expect shares to hit the market soon.**

AI Summary

Alto Neuroscience, Inc. filed an S-1/A on January 29, 2024, which is an amendment to their initial S-1 registration statement (No. 333-276495) for a proposed public offering. This filing updates details for their upcoming IPO, indicating they are moving closer to selling securities to the public. For investors, this means Alto Neuroscience is progressing towards becoming a publicly traded company, offering an opportunity to invest in a pharmaceutical preparations company (SIC 2834) focused on neuroscience, but also signaling the potential for dilution for existing shareholders.

Why It Matters

This S-1/A filing signals Alto Neuroscience's imminent initial public offering, providing an opportunity for new investors to buy shares and for existing shareholders to see their holdings become publicly tradable.

Risk Assessment

Risk Level: high — As an early-stage pharmaceutical company, Alto Neuroscience faces significant risks related to drug development, regulatory approvals, and market acceptance, making its IPO inherently high-risk.

Analyst Insight

Investors interested in the pharmaceutical sector, particularly neuroscience, should monitor Alto Neuroscience's upcoming IPO for potential investment opportunities, while also conducting due diligence on its drug pipeline and financial health given the inherent risks of the industry.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of this S-1/A filing by Alto Neuroscience, Inc.?

The S-1/A filing, dated January 29, 2024, is an Amendment No. 1 to the original Form S-1 Registration Statement (No. 333-276495). Its primary purpose is to update and amend the registration statement in preparation for the proposed sale of securities to the public, indicating the company is moving closer to its initial public offering.

When was this S-1/A filing submitted to the SEC?

This S-1/A filing was filed with the Securities and Exchange Commission on January 29, 2024, as indicated by the 'As filed with the Securities and Exchange Commission on January 29, 2024' statement and the 'FILED AS OF DATE: 20240129' in the header.

Who is listed as the President and Chief Executive Officer of Alto Neuroscience, Inc.?

Amit Etkin, M.D., Ph.D. is listed as the President and Chief Executive Officer of Alto Neuroscience, Inc., with a business address at 369 South San Antonio Road, Los Altos, CA 94022 and telephone number (650) 200-0412.

What is Alto Neuroscience, Inc.'s Standard Industrial Classification (SIC) Code?

Alto Neuroscience, Inc.'s Standard Industrial Classification (SIC) Code is 2834, which corresponds to 'PHARMACEUTICAL PREPARATIONS', as stated in the filing's company data.

Which law firms are representing Alto Neuroscience, Inc. and the underwriters, respectively, in this offering?

Cooley LLP, specifically Divakar Gupta, Christina T. Roupas, Courtney M.W. Tygesson, and Laurie Bauer, are listed as counsel for Alto Neuroscience, Inc. Latham & Watkins LLP, specifically Nathan Ajiashvili, Christopher Lueking, and Ross McAloon, are listed as counsel for the underwriters.

From the Filing

0001193125-24-017403.txt : 20240129 0001193125-24-017403.hdr.sgml : 20240129 20240129073636 ACCESSION NUMBER: 0001193125-24-017403 CONFORMED SUBMISSION TYPE: S-1/A PUBLIC DOCUMENT COUNT: 49 FILED AS OF DATE: 20240129 DATE AS OF CHANGE: 20240129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1/A SEC ACT: 1933 Act SEC FILE NUMBER: 333-276495 FILM NUMBER: 24570110 BUSINESS ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 S-1/A 1 d204454ds1a.htm S-1/A S-1/A Table of Contents As filed with the Securities and Exchange Commission on January 29, 2024. Registration No. 333-276495 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Alto Neuroscience, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 83-4210124 (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Alto Neuroscience, Inc. 369 South San Antonio Road Los Altos, CA 94022 Tel: (650) 200-0412 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices) Amit Etkin, M.D., Ph.D. President and Chief Executive Officer Alto Neuroscience, Inc. 369 South San Antonio Road Los Altos, CA 94022 Tel: (650) 200-0412 (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service) Copies to: Divakar Gupta Christina T. Roupas Courtney M.W. Tygesson Laurie Bauer Cooley LLP 110 North Wacker Drive Suite 4200 Chicago, IL 60606 Tel: (312) 881-6500 Nicholas Smith Chief Financial Officer Alto Neuroscience, Inc. 369 South San Antonio Road Los Altos, CA 94022 Tel: (650) 200-0412 Nathan Ajiashvili Christopher Lueking Ross McAloon Latham & Watkins LLP 1271 Avenue of the Americas New York, NY 10020 Tel: (212) 906-1200 Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐ If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth com

View on Read The Filing